RESUMO

 Hepatic involvement in AL amyloidosis may present as acute liver failure. Historically, liver transplantation in these cases has achieved poor outcomes due to progress of amyloidosis and non-hepatic organ damage. In the era of bortezomib treatment, the prognosis of AL amyloidosis has been markedly improved and may also result in better post-transplant outcomes. We present a case of isolated acute liver failure caused by AL amyloidosis, bridged to transplantation with bortezomib and treated with sequential orthotopic liver transplantation (OLT) and autologous stem cell transplantation. The patient is in stable remission 3 years after OLT.

Assuntos

Amiloidose/terapia , Antineoplásicos/uso terapêutico , Bortezomib/uso terapêutico , Falência Hepática Aguda/terapia , Transplante de Fígado , Transplante de Células-Tronco de Sangue Periférico , Amiloidose/complicações , Humanos , Amiloidose de Cadeia Leve de Imunoglobulina , Falência Hepática Aguda/etiologia , Masculino , Pessoa de Meia-Idade , Transplante Autólogo